Tunisia Pharmaceutical Market Size, Share & Trends Analysis Report By Formulation (Tablets, Injectables, Sprays (BFS-mode, Non-BFS-mode), Suspensions, Capsules, Powders), And Segment Forecasts, 2021 - 2028

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Research Methodology
                   1.2 Research Assumptions
                       1.2.1 Estimates and Forecast Timeline
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 GVR’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis
                           1.6.1.1 Approach 1: Commodity Flow Approach
                               1.6.1.1.1 Market Modeling:
                               1.6.1.1.2 Parameters Assessed To Derive Total Market Size:
                               1.6.1.1.3 Value chain analysis: Tunisian healthcare system
                           1.6.1.2 Approach 2: Country-wise market estimation, using BOTTOM-UP approach
                   1.7 Market: CAGR Calculation
                   1.8 List of Secondary Sources
                   1.9 List of Primary Sources
                   1.10 Objectives
                       1.10.1 Objective 1:
                       1.10.2 Objective 2:
Chapter 2 Tunisia Pharmaceutical Market: Market Summary
                   2.1 Market Summary
Chapter 3 Tunisia Pharmaceutical Market: Industry Outlook
                   3.1 Market Dynamics
                       3.1.1 Market Driver Analysis
                           3.1.1.1 Increase in pharmaceutical R&D spending
                           3.1.1.2 Rise in focus toward healthcare needs
                       3.1.2 Market Restraint Analysis
                           3.1.2.1 Lack of robust reforms to regulate and standardize the pharmaceutical industry
                       3.1.3 Market opportunity Analysis
                           3.1.3.1 Increasing investment and funding programs
                       3.1.4 Market challenge Analysis
                           3.1.4.1 Lack of skilled professionals
                   3.2 Trade Analysis: Tunisia
                       3.2.1 Export Analysis
                           3.2.1.1 Total Export Value, 2011- 2019
                           3.2.1.2 Export Destinations/Top Trading Partners/Main Customers, by region (% of Exports)
                           3.2.1.3 Key Participants (Top Companies) Analysis
                       3.2.2 Import Analysis
                           3.2.2.1 Total Import Value, 2011- 2019
                           3.2.2.2 Import Destinations/Top Trading Partners/Main Suppliers, by region (% of Exports)
                   3.3 Trade Analysis: Middle East & Africa
                       3.3.1 Import Analysis
                       3.3.2 Demand for Pharmaceutical Products in Middle East & Africa
                       3.3.3 Future Trends & Scenario
                   3.4 Pricing and Affordability Analysis of Medicines in Tunisia
                       3.4.1 Price Proposal, 2019
                           3.4.1.1 Proposal Requirements
                           3.4.1.2 Certification of proposal
                           3.4.1.3 Comparative price listing
                   3.5 Regulatory Framework
                   3.6 Tunisia Pharmaceutical Industry Analysis: COVID-19 Impact Analysis
                   3.7 SWOT Analysis; By factor (Political & Legal, Economic, and Technological)
                   3.8 Porter’s Five Forces Analysis
Chapter 4 Tunisia Pharmaceutical Market Formulation Outlook
                   4.1 Tunisia Pharmaceutical Industry Analysis: Formulation Movement Analysis
                   4.2 Tablets
                       4.2.1 Tunisia pharmaceutical industry analysis for tablets estimates and forecast, 2017 - 2028 (USD Million)
                   4.3 Capsules
                       4.3.1 Tunisia pharmaceutical industry analysis for capsules estimates and forecast, 2017 - 2028 (USD Million)
                   4.4 Injectable
                       4.4.1 Tunisia pharmaceutical industry analysis for injectable estimates and forecast, 2017 - 2028 (USD Million)
                       4.4.2 BFS-mode
                           4.4.2.1 Tunisia pharmaceutical industry analysis for BFS-mode injectable estimates and forecast, 2017 - 2028 (USD Million)
                       4.4.3 Non-BFS-mode
                           4.4.3.1 Tunisia pharmaceutical industry analysis for NON-BFS-mode injectable estimates and forecast, 2017 - 2028 (USD Million)
                   4.5 Sprays/Aerosol
                       4.5.1 Tunisia pharmaceutical industry analysis for Sprays/Aerosol estimates and forecast, 2017 - 2028 (USD Million)
                       4.5.2 BFS-mode
                           4.5.2.1 Tunisia pharmaceutical industry analysis for BFS-mode Sprays/Aerosol estimates and forecast, 2017 - 2028 (USD Million)
                       4.5.3 Non-BFS-mode
                           4.5.3.1 Tunisia pharmaceutical industry analysis for NON-BFS-mode Sprays/Aerosol estimates and forecast, 2017 - 2028 (USD Million)
                   4.6 Suspensions
                       4.6.1 Tunisia pharmaceutical industry analysis for Suspensions estimates and forecast, 2017 - 2028 (USD Million)
                       4.6.2 BFS-mode
                           4.6.2.1 Tunisia pharmaceutical industry analysis for BFS-mode Suspensions estimates and forecast, 2017 - 2028 (USD Million)
                       4.6.3 Non-BFS-mode
                           4.6.3.1 Tunisia pharmaceutical industry analysis for non-BFS-mode Suspensions estimates and forecast, 2017 - 2028 (USD Million)
                   4.7 Powders
                       4.7.1 Tunisia pharmaceutical industry analysis for Powders estimates and forecast, 2017 - 2028 (USD Million)
                   4.8 Other Formulations
                       4.8.1 Tunisia pharmaceutical industry analysis for Other Formulations estimates and forecast, 2017 - 2028 (USD Million)
                       4.8.2 BFS-mode
                           4.8.2.1 Tunisia pharmaceutical industry analysis for Other Formulations BFS-mode estimates and forecast, 2017 - 2028 (USD Million)
                       4.8.3 NON-BFS-mode
                           4.8.3.1 Tunisia pharmaceutical industry analysis for Other Formulations NON-BFS-mode estimates and forecast, 2017 - 2028 (USD Million)
Chapter 5 COMPETITIVE LANDSCAPE
                   5.1 Company Market Share Analysis (Top 10 Players)
                   5.2 Company Profiles
                       5.2.1 ADWYA
                           5.2.1.1 Company overview
                           5.2.1.2 Financial Performance
                           5.2.1.3 Product benchmarking
                       5.2.2 Sanofi (sanofi-aventis Tunisia)
                           5.2.2.1 Company overview
                           5.2.2.2 Product benchmarking
                           5.2.2.3 Strategic initiatives
                       5.2.3 TERIAK
                           5.2.3.1 Company overview
                           5.2.3.2 Product benchmarking
                       5.2.4 Opalia pharma
                           5.2.4.1 Company overview
                           5.2.4.2 Financial Performance
                           5.2.4.3 Product benchmarking
                       5.2.5 Les Laboratoires UNIMED
                           5.2.5.1 Company overview
                           5.2.5.2 Product benchmarking
                       5.2.6 MEDIS
                           5.2.6.1 Company overview
                           5.2.6.2 Product benchmarking
                           5.2.6.3 Strategic initiatives
                       5.2.7 Taha Pharma
                           5.2.7.1 Company overview
                           5.2.7.2 Product benchmarking
                       5.2.8 Cytopharma
                           5.2.8.1 Company overview
                           5.2.8.2 Product benchmarking
                   5.3 Vendor Landscape
                       5.3.1 Distributor Analysis
                       5.3.2 Technology Supplier
                   5.4 Synergy Analysis: Major Deals & Strategic Alliances

List of Tables

Table 1 Delivery channels of healthcare system
Table 2 List of secondary sources include, but are not limited to:
Table 3 Export destinations/top trading partners/main customers, by country (% of Exports)
Table 4 Top trading partners/ main suppliers, by region (% of imports)
Table 5 Middle East & Africa import analysis (USD Million)
Table 6 Most commonly used drugs in COVID-19 treatment: Tunisia
Table 7 TERIAK product portfolio: Tablet formulation
Table 8 Medis product portfolio: Injectable formulation
Table 9 List of wholesale distributors in Tunisia

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Value chain analysis: Tunisian healthcare system
Fig. 9 Market snapshot (USD Million)
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Research & development centers dedicated to the pharmaceutical sector
Fig. 12 Competitiveness centers, technopoles, and cyber parks
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Market opportunity relevance analysis (Current & future impact)
Fig. 15 Market challenge relevance analysis (Current & future impact)
Fig. 16 Total export value, USD Million, 2011- 2019
Fig. 17 Total import value, USD Million, 2011- 2019
Fig. 18 Current pricing dynamics associated with the pharmaceutical industry in Tunisia (Part A)
Fig. 19 Present pricing dynamics associated with the pharmaceutical industry in Tunisia (Part B)
Fig. 20 Present pricing dynamics associated with the pharmaceutical industry in Tunisia (Part C)
Fig. 21 COVID-19 cases in Tunisia (February 2020 – 14th April 2021)
Fig. 22 Companies shares having improved IT infrastructure during pandemic (As of December 2020)
Fig. 23 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 24 Porter’s Five Forces Analysis
Fig. 25 Tunisia pharmaceutical industry analysis: Formulation outlook key takeaways
Fig. 26 Tunisia pharmaceutical industry analysis: Formulation outlook movement analysis
Fig. 27 Tunisia pharmaceutical industry analysis for tablets estimates and forecast, 2017 - 2028 (USD Million)
Fig. 28 Tunisia pharmaceutical industry analysis for capsules estimates and forecast, 2017 - 2028 (USD Million)
Fig. 29 Tunisia pharmaceutical industry analysis for injectable estimates and forecast, 2017 - 2028 (USD Million)
Fig. 30 Tunisia pharmaceutical industry analysis for BFS-mode injectable estimates and forecast, 2017 - 2028 (USD Million)
Fig. 31 Tunisia pharmaceutical industry analysis for non-BFS-mode injectable estimates and forecast, 2017 - 2028 (USD Million)
Fig. 32 Sprays/aerosol formulation overview
Fig. 33 Tunisia pharmaceutical industry analysis for sprays/ aerosol estimates and forecast, 2017 - 2028 (USD Million)
Fig. 34 Tunisia pharmaceutical industry analysis for BFS-mode sprays/aerosol estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 Tunisia pharmaceutical industry analysis for non-BFS-mode sprays/aerosol estimates and forecast, 2017 - 2028 (USD Million)
Fig. 36 Tunisia pharmaceutical industry analysis for suspensions estimates and forecast, 2017 - 2028 (USD Million)
Fig. 37 Tunisia pharmaceutical industry analysis for BFS-mode suspensions estimates and forecast, 2017 - 2028 (USD Million)
Fig. 38 Tunisia pharmaceutical industry analysis for non-BFS-mode suspensions estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 Classification of powders based on dispensing
Fig. 40 Tunisia pharmaceutical industry analysis for powders estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 Overview of transdermal drug delivery systems
Fig. 42 Tunisia pharmaceutical industry analysis for other formulations estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 Tunisia pharmaceutical industry analysis for other formulations BFS-mode estimates and forecast, 2017 - 2028 (USD Million)
Fig. 44 Tunisia pharmaceutical industry analysis for other formulations non-BFS-mode estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 Company market share analysis, 2020 (Top 10 players)